Accessibility navigation


Technology evaluation: Colostrinin (ReGen)

Rattray, M. (2005) Technology evaluation: Colostrinin (ReGen). Current Opinion in Molecular Therapeutics, 7 (1). pp. 78-84. ISSN 1464-8431

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Official URL: http://www.ncbi.nlm.nih.gov/pubmed/15732533

Abstract/Summary

ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
No Reading authors. Back catalogue items
ID Code:15727
Uncontrolled Keywords:Alzheimer Disease/*drug therapy Animals Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Colostrum/*chemistry Female Humans PC12 Cells Peptides/*chemistry/metabolism/pharmacokinetics/*therapeutic use Pregnancy Rats

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation